Edge advances in nanodrug therapies for osteoarthritis treatment DOI Creative Commons
Jinfeng Liao, Qinxuan Gu,

Zheng Liu

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 30, 2024

As global population and lifestyles change, osteoarthritis (OA) is becoming a major healthcare challenge world. OA, chronic condition characterized by inflammatory degeneration, often present with joint pain can lead to irreversible disability. While there currently no cure for it commonly managed using nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, glucosamine. Although these treatments alleviate symptoms, difficult effectively deliver sustain therapeutic agents within joints. The emergence of nanotechnology, particularly in form smart nanomedicine, has introduced innovative approaches OA treatment. Nanotherapeutic strategies offer promising advantages, including more precise targeting affected areas, prolonged effects, enhanced bioavailability, reduced systemic toxicity compared traditional treatments. nanoparticles show potential as viable delivery system therapies based on encouraging lab-based clinical trials results, remails considerable gap between current research application. This review highlights recent advances nanotherapy explore future pathways refine optimize strategies.

Language: Английский

Advancements in rheumatoid arthritis therapy: a journey from conventional therapy to precision medicine via nanoparticles targeting immune cells DOI

Anwesha Laha,

Simran Nasra, Dhiraj Bhatia

et al.

Nanoscale, Journal Year: 2024, Volume and Issue: 16(32), P. 14975 - 14993

Published: Jan. 1, 2024

Rheumatoid arthritis (RA) is a progressive autoimmune disease that mainly affects the inner lining of synovial joints and leads to chronic inflammation. While RA not known as lethal, recent research indicates it may be silent killer because its strong association with an increased risk lung heart diseases. Patients develop these systemic consequences due regular uptake heavy drugs such disease-modifying antirheumatic medications (DMARDs), glucocorticoids (GCs), nonsteroidal anti-inflammatory medicines (NSAIDs),

Language: Английский

Citations

6
Enhanced Metabolic Syndrome Management Through Cannabidiol‐Loaded PLGA Nanoparticles: Development and In Vitro Evaluation DOI
Mazen M. El‐Hammadi,

Lucía Martín‐Navarro,

Esther Berrocoso

et al.

Journal of Biomedical Materials Research Part A, Journal Year: 2025, Volume and Issue: 113(5)

Published: April 25, 2025

ABSTRACT Cannabidiol (CBD) holds promise for managing metabolic diseases, yet enhancing its oral bioavailability and efficacy remains challenging. To address this, we developed polymeric nanoparticles (NPs), using poly(lactic‐co‐glycolic acid) (PLGA), encapsulating CBD nanoprecipitation, aiming to create an effective CBD‐nanoformulation disorder treatment. These NPs (135–265 nm) demonstrated high encapsulation efficiency (EE% ≈ 100%) sustained release kinetics. Their therapeutic potential was evaluated in vitro syndrome model employing sodium palmitate‐induced HepG2 cells. Key assessment parameters included cell viability (MTT assay), glucose uptake, lipid accumulation (Oil Red O staining), triglycerides, cholesterol, HDL‐c levels, gene expression of regulators. Results showed IC50 9.85 μg/mL free 11.26 CBD‐loaded NPs. significantly enhanced reduced content, lowered triglycerides total increased levels compared CBD. Gene analysis indicated gluconeogenesis via downregulation PPARγ, FOXO‐1, PEPCK, G6Pase fatty acid oxidation through CPT‐1 upregulation. findings suggest that may serve as a novel strategy the management disorders, warranting further vivo studies.

Language: Английский

Citations

0
Cannabidiol-Loaded Lipid Nanoparticles Incorporated in Polyvinyl Alcohol and Sodium Alginate Hydrogel Scaffold for Enhancing Cell Migration and Accelerating Wound Healing DOI Creative Commons
Sarawut Lapmanee, Sakkarin Bhubhanil, Natthawut Charoenphon

et al.

Gels, Journal Year: 2024, Volume and Issue: 10(12), P. 843 - 843

Published: Dec. 20, 2024

Chronic wounds represent a persistent clinical challenge due to prolonged inflammation and impaired tissue repair mechanisms. Cannabidiol (CBD), recognized for its anti-inflammatory pro-healing properties, shows therapeutic promise in wound care. However, delivery via lipid nanoparticles (LNPs) remains challenging CBD’s inherent instability low bioavailability. This study developed characterized novel hydrogel scaffold composed of CBD-loaded LNPs (CBD/LNPs) integrated into polyvinyl alcohol (PVA) sodium alginate (SA) matrix, designed enhance mitigate inflammation. The characteristics the were observed including degree swelling LNPs’ release profiles. Furthermore, results, CBD/LNPs displayed enhanced stability reduced cytotoxicity compared unencapsulated CBD. In vitro assays demonstrated that significantly promoted fibroblast migration gap-closure models intracellular reactive oxygen species, supporting their potential as biocompatible efficacious agent cellular oxidative stress attenuation. vivo experiments using adult male Wistar rats with aseptic cutaneous revealed treatment CBD/LNP-PVA/SA accelerated closure relative blank controls, demonstrating substantial reduction area over time. Histological analysis confirms notable improvements skin morphology treated evidence epithelialization, collagen deposition, increased dermal thickness vascularization. Additionally, histology showed more organized epidermal layer inflammatory cell infiltration scaffold-treated wounds, corresponding 35% increase rate by day 28 post-treatment. These findings suggest scaffolds facilitate resolution structural healing through localized, sustained CBD delivery. dual wound-healing effects position promising approach chronic management. Future investigations are warranted elucidate mechanistic pathways which modulates architecture explore translational applications

Language: Английский

Citations

2
Chondroitin Sulfate for Cartilage Regeneration, Administered Topically Using a Nanostructured Formulation DOI Open Access
Marta E. Bustos Araya, Anna Nardi-Ricart,

Ana C. Calpena Capmany

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(18), P. 10023 - 10023

Published: Sept. 18, 2024

In the pharmaceutical sector, solid lipid nanoparticles (SLN) are vital for drug delivery incorporating a core. Chondroitin sulfate (CHON) is crucial cartilage health. It often used in osteoarthritis (OA) treatment. Due to conflicting results from clinical trials on CHON’s efficacy OA treatment, there has been shift toward exploring effective topical systems utilizing nanotechnology. This study aimed optimize nanoparticle formulation aiming enhance CHON permeation therapy. A 3 × 2 Design of these experiments determined ideal parameters: concentration 0.4 mg/mL, operating at 20,000 rpm speed, and processing 10 min SLN production. Transmission electron microscopy analysis confirmed nanoparticles’ spherical morphology, ensuring uniformity efficient delivery. Cell viability assessments showed no significant cytotoxicity within tested parameters, indicating safe profile potential application. The cell internalization assay indicates successful 1.5 h 24 post-treatment. Biopharmaceutical studies supported SLNs, them be carriers through skin, showcasing improved skin retention compared conventional methods. summary, this successfully optimized transport pig ear with cellular toxicity, highlighting SLNs’ as promising treatment advance nanotechnology-based therapeutic strategies formulations.

Language: Английский

Citations

2
Edge advances in nanodrug therapies for osteoarthritis treatment DOI Creative Commons
Jinfeng Liao, Qinxuan Gu,

Zheng Liu

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 30, 2024

As global population and lifestyles change, osteoarthritis (OA) is becoming a major healthcare challenge world. OA, chronic condition characterized by inflammatory degeneration, often present with joint pain can lead to irreversible disability. While there currently no cure for it commonly managed using nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, glucosamine. Although these treatments alleviate symptoms, difficult effectively deliver sustain therapeutic agents within joints. The emergence of nanotechnology, particularly in form smart nanomedicine, has introduced innovative approaches OA treatment. Nanotherapeutic strategies offer promising advantages, including more precise targeting affected areas, prolonged effects, enhanced bioavailability, reduced systemic toxicity compared traditional treatments. nanoparticles show potential as viable delivery system therapies based on encouraging lab-based clinical trials results, remails considerable gap between current research application. This review highlights recent advances nanotherapy explore future pathways refine optimize strategies.

Language: Английский

Citations

1